

- 1: Viitala A, Anttinen M, Mäkelä P, Pärssinen H, Nurminen P, Sainio T, Saunavaara J, Taimen P, Sequeiros RB, Boström PJ. Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic obstruction: 1-year clinical outcomes of a phase II study. *BJU Int*. 2025 May 28. doi: 10.1111/bju.16795. Epub ahead of print. PMID: 40432395.
- 2: Kivikallio A, Malaspina S, Saarinen I, Seppänen M, Anttinen M, Jambor I, Verho J, Kemppainen J, Aronen HJ, Boström PJ, Ettala O, Taimen P. Prospective comparison of ¹⁸F-PSMA-1007 PET/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer. *Eur J Nucl Med Mol Imaging*. 2025 Mar 31. doi: 10.1007/s00259-025-07208-z. Epub ahead of print. PMID: 40159542.
- 3: Anttinen M, Mäkelä P, Nurminen P, Pärssinen H, Malaspina S, Sainio T, Högerman M, Taimen P, Blanco Sequeiros R, Boström PJ. Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer. *Eur Urol Open Sci*. 2024 Dec 5;71:69-77. doi: 10.1016/j.euros.2024.11.001. PMID: 39703741; PMCID: PMC11656090.
- 4: Seikkula H, Mäkelä L, Visapää H, Anttinen M. Optimal Strategies for Managing Prostate-specific Antigen Recurrence After Primary Radiotherapy in Prostate Cancer: The Finnish Perspective. *Eur Urol Focus*. 2023 Sep;9(5):698-700. doi: 10.1016/j.euf.2023.11.008. Epub 2023 Nov 21. PMID: 37989649.
- 5: Mäkelä P, Anttinen M, Wright C, Sainio T, Boström PJ, Sequeiros RB. Evolution of non-perfused volume after transurethral ultrasound ablation of prostate: A retrospective 12-month analysis. *Eur J Radiol Open*. 2023 Jul 6;11:100506. doi: 10.1016/j.ejro.2023.100506. PMID: 37456928; PMCID: PMC10339207.
- 6: Wright C, Mäkelä P, Bigot A, Anttinen M, Boström PJ, Blanco Sequeiros R. Deep learning prediction of non-perfused volume without contrast agents during prostate ablation therapy. *Biomed Eng Lett*. 2022 Nov 8;13(1):31-40. doi: 10.1007/s13534-022-00250-y. PMID: 36711157; PMCID: PMC9873841.
- 7: Repo O, Oranges CM, di Summa PG, Uusalo P, Anttinen M, Giordano S. Scarpa Fascia Preservation to Reduce Seroma Rate on Massive Weight Loss Patients Undergoing Abdominoplasty: A Comparative Study. *J Clin Med*. 2023 Jan 13;12(2):636. doi: 10.3390/jcm12020636. PMID: 36675566; PMCID: PMC9862610.
- 8: Arvola S, Seppänen M, Timonen KL, Rautio P, Ettala O, Anttinen M, Boström PJ, Nojonen T. Detection of prostate cancer bone metastases with fast whole-body ^{99m}Tc-HMDP SPECT/CT using a general-purpose CZT system. *EJNMMI Phys*. 2022 Dec 12;9(1):85. doi: 10.1186/s40658-022-00517-4. PMID: 36508016; PMCID: PMC9743860.
- 9: Anttinen M, Blanco Sequeiros R, Boström PJ, Taimen P. Evolving imaging methods of prostate cancer and the emergence of magnetic resonance imaging guided ablation techniques. *Front Oncol*. 2022 Nov 17;12:1043688. doi: 10.3389/fonc.2022.1043688. PMID: 36465377; PMCID: PMC9714456.

- 10: Mäkelä P, Wright C, Anttinen M, Boström PJ, Blanco Sequeiros R. Safety and efficacy of MRI-guided transurethral ultrasound ablation for radiorecurrent prostate cancer in the presence of gold fiducial markers. *Acta Radiol.* 2023 Mar;64(3):1228-1237. doi: 10.1177/02841851221108292. Epub 2022 Jun 24. PMID: 35748746.
- 11: Arvola S, Seppänen M, Malaspina S, Mätzke S, Raiko J, Timonen KL, Ettala O, Jambor I, Anttinen M, Kuisma A, Löyttyniemi E, Boström PJ, Sohlberg A, Noponen T. Comparison of reprojected bone SPECT/CT and planar bone scintigraphy for the detection of bone metastases in breast and prostate cancer. *Nucl Med Commun.* 2022 May 1;43(5):510-517. doi: 10.1097/MNM.0000000000001536. PMID: 35081092.
- 12: Wright C, Mäkelä P, Anttinen M, Sainio T, Boström PJ, Blanco Sequeiros R. Fiducial markers and their impact on ablation outcome for patients treated with MR-guided transurethral ablation (TULSA): a retrospective technical analysis. *Int J Hyperthermia.* 2021;38(1):1677-1684. doi: 10.1080/02656736.2021.2008519. PMID: 34927517.
- 13: Anttinen M, Mäkelä P, Viitala A, Nurminen P, Suomi V, Sainio T, Saunavaara J, Taimen P, Sequeiros RB, Boström PJ. Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer: 12-Month Functional and Oncological Results. *Eur Urol Open Sci.* 2020 Nov 25;22:79-87. doi: 10.1016/j.euros.2020.10.007. PMID: 34337481; PMCID: PMC8317885.
- 14: Viitala A, Anttinen M, Wright C, Virtanen I, Mäkelä P, Hovinen T, Sainio T, Saunavaara J, Taimen P, Blanco Sequeiros R, Boström PJ. Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study. *BJU Int.* 2022 Feb;129(2):208-216. doi: 10.1111/bju.15523. Epub 2021 Jul 16. PMID: 34161649.
- 15: Malaspina S, Anttinen M, Taimen P, Löyttyniemi E, Kemppainen J, Seppänen M, Boström P, Ettala O. Response to the Letter to the Editor: Prospective comparison of ¹⁸F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. *Eur J Nucl Med Mol Imaging.* 2021 Aug;48(9):2672-2673. doi: 10.1007/s00259-021-05428-7. Epub 2021 Jun 14. PMID: 34128091.
- 16: Malaspina S, Anttinen M, Taimen P, Jambor I, Sandell M, Rinta-Kiikka I, Kajander S, Schildt J, Saukko E, Noponen T, Saunavaara J, Dean PB, Sequeiros RB, Aronen HJ, Kemppainen J, Seppänen M, Boström PJ, Ettala O. Prospective comparison of ¹⁸F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. *Eur J Nucl Med Mol Imaging.* 2021 Aug;48(9):2951-2959. doi: 10.1007/s00259-021-05296-1. Epub 2021 Mar 13. PMID: 33715033; PMCID: PMC8263440.
- 17: Mäkelä P, Anttinen M, Suomi V, Steiner A, Saunavaara J, Sainio T, Horte A, Taimen P, Boström P, Blanco Sequeiros R. Acute and subacute prostate MRI findings after MRI-guided transurethral ultrasound ablation of prostate cancer. *Acta Radiol.* 2021 Dec;62(12):1687-1695. doi: 10.1177/0284185120976931. Epub 2020

Nov 28. PMID: 33251811.

18: Anttinen M, Mäkelä P, Nurminen P, Yli-Pietilä E, Suomi V, Sainio T, Saunavaara J, Taimen P, Blanco Sequeiros R, Boström PJ. Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer. *Scand J Urol*. 2020 Dec;54(6):481-486. doi: 10.1080/21681805.2020.1814857. Epub 2020 Sep 8. PMID: 32897169.

19: Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, Rinta-Kiikka I, Schildt J, Saukko E, Rautio P, Timonen KL, Matikainen T, Noponen T, Saunavaara J, Löyttyniemi E, Taimen P, Kemppainen J, Dean PB, Blanco Sequeiros R, Aronen HJ, Seppänen M, Boström PJ. A Prospective Comparison of ¹⁸F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). *Eur Urol Oncol*. 2021 Aug;4(4):635-644. doi: 10.1016/j.euo.2020.06.012. Epub 2020 Jul 13. PMID: 32675047.

20: Anttinen M, Mäkelä P, Suomi V, Kiviniemi A, Saunavaara J, Sainio T, Horte A, Eklund L, Taimen P, Sequeiros RB, Boström PJ. Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer. *Scand J Urol*. 2019 Oct;53(5):295-302. doi: 10.1080/21681805.2019.1660707. Epub 2019 Sep 26. PMID: 31556779.

21: Anttinen M, Yli-Pietilä E, Suomi V, Mäkelä P, Sainio T, Saunavaara J, Eklund L, Blanco Sequeiros R, Taimen P, Boström PJ. Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells. *Int J Hyperthermia*. 2019;36(1):915-925. doi: 10.1080/02656736.2019.1652773. PMID: 31466481.

22: Salminen AP, Koskinen I, Perez IM, Hurme S, Murtola TJ, Vaarala MH, Nykopp TK, Seppänen M, Isotalo T, Marttila T, Levomäki L, Becker S, Anttinen M, Liukkonen T, Säily M, Pogodin-Hannolainen D, Viitanen J, Palmberg C, Ottelin J, Sairanen J, Ettala OO, Boström PJ. Neoadjuvant Chemotherapy Does Not Increase the Morbidity of Radical Cystectomy: A 10-year Retrospective Nationwide Study. *Eur Urol Oncol*. 2018 Dec;1(6):525-530. doi: 10.1016/j.euo.2018.06.014. Epub 2018 Jul 14. PMID: 31158099.

23: Suomi V, Treeby B, Jaros J, Makela P, Anttinen M, Saunavaara J, Sainio T, Kiviniemi A, Blanco R. Transurethral ultrasound therapy of the prostate in the presence of calcifications: A simulation study. *Med Phys*. 2018 Nov;45(11):4793-4805. doi: 10.1002/mp.13183. Epub 2018 Oct 1. PMID: 30216469.

24: Anttinen M, Paajanen H. Kroonisen nivuskivun monet kasvot--harvinaisuudetkin muistettava [The many causes of chronic pain in the groin]. *Duodecim*. 2014;130(19):1940-3. Finnish. PMID: 25558615.

25: Bernoulli J, Yarkin E, Laakso A, Anttinen M, Bosland M, Vega K, Kallajoki M,

Santti R, Pylkkänen L. Histopathological evidence for an association of inflammation with ductal pin-like lesions but not with ductal adenocarcinoma in the prostate of the noble rat. *Prostate*. 2008 May 15;68(7):728-39. doi: 10.1002/pros.20719. PMID: 18302197.